Balyasny Asset Management LLC Exelixis, Inc. Call Options Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $574,845 - $682,005	28,500 New	28,500 $676,000
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $2.17 Million - $2.44 Million	-119,200 Reduced 30.56%	270,800 $5.17 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $6.36 Million - $7.57 Million	390,000 New	390,000 $7.57 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $224,375 - $319,500	12,500 Added 6.25%	212,500 $3.87 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $4.85 Million - $6.19 Million	200,000	200,000 $6.08 Million

460

246M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.07B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.